- 著者
- Yingying Ding Huamei Yan Zhen Ning Xiaofeng Cai Yin Yang Rong Pan Yanqiu Zhou Huang Zheng Meiyang Gao Keming Rou Zunyou Wu Na He
- 出版者
- バイオ&ソーシャル・サイエンス推進国際研究交流会
- 雑誌
- BioScience Trends (ISSN:18817815)
- 巻号頁・発行日
- pp.2016.01035, (Released:2016-04-06)
- 参考文献数
- 21
- 被引用文献数
- 56
Little is known about the acceptance and actual uptake of pre-exposure prophylaxis (PrEP) and associated factors in men who have sex with men (MSM) in China. This study is the baseline survey of an intervention study designed to evaluate the effectiveness of tenofovirdisoproxil fumarate (TDF) on a daily use for human immunodeficiency virus (HIV) prevention among MSM in Shanghai, China. From October 2012 to December 2013, a total of 1,033 MSM in Shanghai were recruited by local district Centers for Disease Control and Prevention (CDC) and a MSM community-based non-governmental organization (NGO). Among them, 197 (19.1%) participants expressed willingness to use the TDF group at baseline survey, but only 26 (2.5%) participated in the TDF group and took TDF one tablet a day. Higher willingness to use PrEP was associated with being 45 years or older, non-local residents, having more male sex partners in the past 6 months and not using condom at last anal sex with man. Acutal uptake of PrEP was associated with having ≥ 11 male sex partners in lifetime and reporting no female sex partners in lifetime. Reasons for not participating in TDF group among those who expressed willingness to use PrEP at baseline survey included loss of contact, ineligiblity because of abnormal results for liver or renal function tests, change of mind, and HIV seroconversion before uptake of PrEP. Our findings suggest that promotion of PrEP in MSM remains challenging at current circumstancein China. Future research is needed to solicit effective education and intervention programs to promote acceptance of PrEP among Chinese MSM.
- 著者
- Na He
- 出版者
- International Research and Cooperation Association for Bio & Socio-Sciences Advancement
- 雑誌
- BioScience Trends (ISSN:18817815)
- 巻号頁・発行日
- pp.2021.01261, (Released:2021-07-01)
- 参考文献数
- 32
- 被引用文献数
- 4
The globe has witnessed the rapid evolution of SARS-CoV-2 mutations and emerging variants of concern (VOCs) and variants of interest (VOIs) that have broadly impacted the transmissibility, antigenicity, morbidity, and mortality of the virus. Although around 2.5 billion vaccine doses have been administered worldwide, vaccine coverage remains far behind the minimum threshold needed to achieve herd immunity overall and it varies substantially by country. Many countries, and especially low- and middle-income countries (LMICs), are struggling with access to COVID-19 vaccines and a lack of personnel to perform mass vaccination. Effective nonpharmaceutical interventions (NPIs) are also not unanimously accepted and strictly complied with by the public and local communities. Moreover, the global fight against COVID-19 is and continues to face geopolitical, social, economic, and human rights concerns. Taken together, these circumstances call for a unified public health response with well-organized individual, local, national, and global efforts and actions to achieve success in controlling the COVID-19 pandemic and achieving sustainable health and development goals.